CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients
Reuters
Dec 18
CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients
CorMedix Inc. announced interim results from its ongoing real-world evidence study of DefenCath, conducted in collaboration with U.S. Renal Care $(USRC)$ in adult hemodialysis patients with central venous catheters. The study began following the outpatient commercial launch of DefenCath in July 2024 and is designed to prospectively assess the rates of catheter-related bloodstream infections (CRBSI) and related hospitalizations over a two-year period. Interim data from approximately 7,000 patients who received at least one dose of DefenCath in the first year indicate a reduction in serious infections and hospitalizations. Additional secondary outcomes, such as missed treatment sessions, antibiotic use, and tPA utilization, are also being evaluated, with further results expected in the future. CorMedix is using this data in ongoing discussions with customers and payers, including Medicare Advantage plans, to support broader access and reimbursement for DefenCath.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604271) on December 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.